Mirodenafil Explained

Mirodenafil belongs to the drug class PDE5 inhibitors, which includes avanafil, sildenafil, tadalafil, udenafil, and vardenafil, and is the first-line treatment for erectile dysfunction. Developed by SK Chemicals Life Science, mirodenafil is marketed in Korea under the trade name Mvix, offered both as tablets (50 mg and 100 mg) and as orally dissolving films (50 mg).

Despite several clinical trials having been conducted,^{[1] [2] [3]} mirodenafil has not been approved for use in the United States by the U.S. Food and Drug Administration.

Notes and References

1. Paick JS, Ahn TY, Choi HK, Chung WS, Kim JJ, Kim SC, Kim SW, Lee SW, Min KS, Moon KH, Park JK, Park K, Park NC, Suh JK, Yang DY, Jung HG . Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction . The Journal of Sexual Medicine . 5 . 11 . 2672–80 . November 2008 . 18638004 . 10.1111/j.1743-6109.2008.00945.x .
2. Kim BH, Yi S, Kim J, Lim KS, Kim KP, Lee B, Shin SG, Jang IJ, Yu KS . Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea . Clinical Therapeutics . 31 . 6 . 1234–43 . June 2009 . 19695390 . 10.1016/j.clinthera.2009.06.008 .
3. Shin KH, Kim BH, Kim TE, Kim JW, Yi S, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS . The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study . Clinical Therapeutics . 31 . 12 . 3009–20 . December 2009 . 20110038 . 10.1016/j.clinthera.2009.12.012 .